<DOC>
	<DOC>NCT01464424</DOC>
	<brief_summary>The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ocular hypertension after 6 weeks of treatment.</brief_summary>
	<brief_title>Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Clinical diagnosis of openangle glaucoma (OAG) or ocular hypertension (OHT) in at least one eye. Nonstudy eye: Intraocular pressure (IOP) able to be controlled with no pharmacologic therapy or on the study medicine alone. Willing to discontinue the use of all other ocular hypotensive medications prior to receiving study medication and for the entire course of the study. Able to follow instructions, self instill study article, and attend all study visits. Bestcorrected Snellen visual acuity of 20/200 or better in each eye. Sign Ethics Committee reviewed and approved informed consent form. Other protocoldefined inclusion criteria may apply. Known medical history of allergy, hypersensitivity or poor tolerance to any component of the preparations used in this study. Any abnormality preventing applanation tonometry in either eye. Dry eye previously or currently being treated with punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids. Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. Intraocular conventional or laser surgery &gt;3 months prior to consent. Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. Progressive retinal or optic nerve disease from any cause. Use of any systemic medications known to affect IOP which have not been on a stable course for at least 7 days prior to Screening or an anticipated change in dosage during the course of the study. Any clinically significant, serious, or severe medical condition. Women of childbearing potential who are pregnant, lactating, or not using reliable means of birth control. Participation in any other study within 30 days prior to Screening. Use of any systemic (oral), injectable or topical steroids. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Intraocular Pressure</keyword>
</DOC>